DK3820446T3 - Farmaceutiske sammensætninger omfattende RPL554 I HFA-134A til indgivelse ved inhalation - Google Patents

Farmaceutiske sammensætninger omfattende RPL554 I HFA-134A til indgivelse ved inhalation Download PDF

Info

Publication number
DK3820446T3
DK3820446T3 DK19790718.1T DK19790718T DK3820446T3 DK 3820446 T3 DK3820446 T3 DK 3820446T3 DK 19790718 T DK19790718 T DK 19790718T DK 3820446 T3 DK3820446 T3 DK 3820446T3
Authority
DK
Denmark
Prior art keywords
rpl554
hfa
inhalation
administration
pharmaceutical compositions
Prior art date
Application number
DK19790718.1T
Other languages
Danish (da)
English (en)
Inventor
Peter Lionel Spargo
Phillip A Haywood
Original Assignee
Verona Pharma Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verona Pharma Plc filed Critical Verona Pharma Plc
Application granted granted Critical
Publication of DK3820446T3 publication Critical patent/DK3820446T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK19790718.1T 2018-10-09 2019-10-09 Farmaceutiske sammensætninger omfattende RPL554 I HFA-134A til indgivelse ved inhalation DK3820446T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1816447.5A GB2578093B (en) 2018-10-09 2018-10-09 Liquid pharmaceutical composition comprising RPL554 and HFA-134A
PCT/GB2019/052863 WO2020074894A1 (en) 2018-10-09 2019-10-09 Pharmaceutical compositions comprising rpl554 in hfa-134a for administration by inhalation

Publications (1)

Publication Number Publication Date
DK3820446T3 true DK3820446T3 (da) 2021-12-06

Family

ID=64394831

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19790718.1T DK3820446T3 (da) 2018-10-09 2019-10-09 Farmaceutiske sammensætninger omfattende RPL554 I HFA-134A til indgivelse ved inhalation

Country Status (27)

Country Link
US (2) US20210379053A1 (cg-RX-API-DMAC7.html)
EP (2) EP3960157A1 (cg-RX-API-DMAC7.html)
JP (2) JP7578587B2 (cg-RX-API-DMAC7.html)
KR (1) KR102960903B1 (cg-RX-API-DMAC7.html)
CN (1) CN112912064B (cg-RX-API-DMAC7.html)
AU (1) AU2019358585B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021006712A2 (cg-RX-API-DMAC7.html)
CA (1) CA3113167A1 (cg-RX-API-DMAC7.html)
CY (1) CY1124943T1 (cg-RX-API-DMAC7.html)
DK (1) DK3820446T3 (cg-RX-API-DMAC7.html)
ES (1) ES2899744T3 (cg-RX-API-DMAC7.html)
GB (1) GB2578093B (cg-RX-API-DMAC7.html)
HR (1) HRP20220053T1 (cg-RX-API-DMAC7.html)
HU (1) HUE057780T2 (cg-RX-API-DMAC7.html)
IL (1) IL282032B2 (cg-RX-API-DMAC7.html)
LT (1) LT3820446T (cg-RX-API-DMAC7.html)
MX (2) MX2021003599A (cg-RX-API-DMAC7.html)
MY (1) MY207302A (cg-RX-API-DMAC7.html)
PH (1) PH12021550767A1 (cg-RX-API-DMAC7.html)
PL (1) PL3820446T3 (cg-RX-API-DMAC7.html)
PT (1) PT3820446T (cg-RX-API-DMAC7.html)
RS (1) RS62775B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202102567UA (cg-RX-API-DMAC7.html)
SI (1) SI3820446T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202200044T1 (cg-RX-API-DMAC7.html)
WO (1) WO2020074894A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202102039B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2773142T3 (es) 2014-05-12 2020-07-09 Verona Pharma Plc Nuevo tratamiento
GB201502260D0 (en) 2015-02-11 2015-04-01 Verona Pharma Plc Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound
GB201916915D0 (en) 2019-11-20 2020-01-01 Amr Centre Ltd Compounds
GB2594480A (en) * 2020-04-28 2021-11-03 Verona Pharma Plc New treatment
GB202202297D0 (en) 2022-02-21 2022-04-06 Verona Pharma Plc Formulation production process
EP4609864A4 (en) * 2022-10-28 2026-02-18 Jiangsu Hengrui Pharmaceuticals Co Ltd PHARMACEUTICAL COMPOSITION CONTAINING AN ISOQUINOLINONE COMPOUND AND RELATED PREPARATION PROCESS
EP4378942A1 (en) 2022-12-02 2024-06-05 Sandoz AG Crystal form of a pde3/4 inhibitor
CN121620356A (zh) 2023-06-26 2026-03-06 维罗纳制药公司 包含恩塞芬汀的颗粒组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1165558T3 (da) 1999-03-31 2004-02-09 Vernalis Ltd Pyrimido[6,1-a]isoquinolin-4-on-derivater
SI2603509T1 (sl) * 2010-08-09 2014-10-30 Verona Pharma Plc Kristalinična oblika spojine PIRIMIDIO(6,1-A) IZOKINOLIN-4-ENA
CN107875127A (zh) * 2012-02-28 2018-04-06 艾塞尤提卡控股公司 可吸入药物组合物
JP6560986B2 (ja) 2013-03-15 2019-08-14 ヴェローナ ファーマ ピーエルシー 複合製剤
ES2773142T3 (es) * 2014-05-12 2020-07-09 Verona Pharma Plc Nuevo tratamiento
LT3193835T (lt) * 2014-09-15 2018-06-11 Verona Pharma Plc Skysta inhaliuojama vaisto forma, apimanti rpl554
GB201502260D0 (en) * 2015-02-11 2015-04-01 Verona Pharma Plc Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound

Also Published As

Publication number Publication date
EP3820446B1 (en) 2021-11-03
US20210379053A1 (en) 2021-12-09
AU2019358585B2 (en) 2025-01-16
GB2578093A (en) 2020-04-22
CN112912064A (zh) 2021-06-04
PL3820446T3 (pl) 2022-03-14
JP2024113096A (ja) 2024-08-21
SMT202200044T1 (it) 2022-05-12
BR112021006712A2 (pt) 2021-07-27
PT3820446T (pt) 2021-12-03
WO2020074894A1 (en) 2020-04-16
SI3820446T1 (sl) 2022-01-31
CY1124943T1 (el) 2023-01-05
CA3113167A1 (en) 2020-04-16
KR20210073532A (ko) 2021-06-18
IL282032B1 (en) 2026-01-01
IL282032A (en) 2021-05-31
ZA202102039B (en) 2022-08-31
ES2899744T3 (es) 2022-03-14
JP7578587B2 (ja) 2024-11-06
GB201816447D0 (en) 2018-11-28
US20250049781A1 (en) 2025-02-13
EP3960157A1 (en) 2022-03-02
GB2578093B (en) 2020-11-18
MY207302A (en) 2025-02-15
RS62775B1 (sr) 2022-01-31
MX2024001499A (es) 2024-02-27
EP3820446A1 (en) 2021-05-19
IL282032B2 (en) 2026-05-01
PH12021550767A1 (en) 2021-10-04
SG11202102567UA (en) 2021-04-29
AU2019358585A1 (en) 2021-04-15
CN112912064B (zh) 2025-02-14
HUE057780T2 (hu) 2022-06-28
JP2022513566A (ja) 2022-02-09
JP7836853B2 (ja) 2026-03-27
KR102960903B1 (ko) 2026-05-04
LT3820446T (lt) 2021-12-10
HRP20220053T1 (hr) 2022-04-15
MX2021003599A (es) 2021-05-28

Similar Documents

Publication Publication Date Title
DK4061344T3 (da) 6-hydroxycannabidiol til anvendelse som lægemiddel
PL3820446T3 (pl) Kompozycje farmaceutyczne zawierające rpl554 w hfa-134a do podawania przez inhalację
DK3253382T3 (da) Farmaceutiske sammensætninger til kombinationsterapi
EP3801457B1 (en) STABLE PHARMACEUTICAL COMPOSITIONS FOR PRESSURIZED DOSE-DOSE INHALATORS
DK3236943T3 (da) Sammensætninger til ileo-jejunal lægemiddeladministration
IL263516B (en) A dosage form for vaporization and smoking
MX376057B (es) Formulaciones de aripiprazol que tienen mayores velocidades de inyeccion.
DK3866767T3 (da) Farmaceutisk sammensætning til oral indgivelse omfattende aminopyrimidinderivat eller salt deraf
DK3735228T3 (da) Programmerbar farmaceutiske sammensætninger til krono-lægemiddelfrigivelse
MA52704A (fr) Préparation pharmaceutique
PL3661373T3 (pl) Kompozycja farmaceutyczna na niedokrwistość
IL285674A (en) Pharmaceutical formulations
DK3897589T3 (da) Farmaceutiske formuleringer indeholdende relacorilant, en heteroaryl-ketonkondenseret azadecalinforbindelse
EP4289478C0 (en) PHARMACEUTICAL COMPOSITION OF EDARAVONE
BR112016024235A2 (pt) composições farmacêuticas compreendendo agentes antibacterianos
DK3773595T3 (da) Farmaceutiske anticancer-sammensætninger til kombineret terapi
DK3908321T3 (da) Farmaceutisk sammensætning
DK3762009T3 (da) Toxin-afledte indgivelseskonstrukter til oral indgivelse
DK4027973T3 (da) Formuleringer til lægemiddeladministration
BR112017024126B8 (pt) Composições farmacêuticas, composto a micronizado e/ou pelo menos um sal farmaceuticamente aceitável micronizado do composto a e uso dos mesmos
DK4076404T3 (da) Farmaceutisk pyrazolsammensætning
PT3949952T (pt) Composição farmacêutica
EP3881841A4 (en) PHARMACEUTICAL COMPOSITION
DK3650024T3 (da) Farmaceutisk sammensætning til nasal indgivelse omfattende rifampiciner til behandling af demens
EP4081251A4 (en) PHARMACEUTICAL COMPOSITIONS